Cargando…

Both “Vitamin L for Life” and “One Milligram of Satan”: A Multi-Perspective Qualitative Exploration of Adjuvant Endocrine Therapy Use after Breast Cancer

Adjuvant endocrine therapy (AET) is recommended after hormone receptor-positive breast cancer to reduce risk of recurrence, but adherence is sub-optimal in many women. Behavioral interventions have been ineffective in improving adherence rates to AET. This qualitative descriptive study investigates...

Descripción completa

Detalles Bibliográficos
Autores principales: Toivonen, Kirsti I., Oberoi, Devesh, King-Shier, Kathryn, Piedalue, Katherine-Ann L., Rash, Joshua A., Carlson, Linda E., Campbell, Tavis S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8293219/
https://www.ncbi.nlm.nih.gov/pubmed/34287250
http://dx.doi.org/10.3390/curroncol28040227
_version_ 1783724987225473024
author Toivonen, Kirsti I.
Oberoi, Devesh
King-Shier, Kathryn
Piedalue, Katherine-Ann L.
Rash, Joshua A.
Carlson, Linda E.
Campbell, Tavis S.
author_facet Toivonen, Kirsti I.
Oberoi, Devesh
King-Shier, Kathryn
Piedalue, Katherine-Ann L.
Rash, Joshua A.
Carlson, Linda E.
Campbell, Tavis S.
author_sort Toivonen, Kirsti I.
collection PubMed
description Adjuvant endocrine therapy (AET) is recommended after hormone receptor-positive breast cancer to reduce risk of recurrence, but adherence is sub-optimal in many women. Behavioral interventions have been ineffective in improving adherence rates to AET. This qualitative descriptive study investigates factors that support women in AET use and suggestions for interventions to improve AET use and management. Interviews with women who persisted with AET (n = 23), women who discontinued AET (n = 15), and healthcare providers (HCPs; oncologists, oncology residents, and pharmacists; n = 9) were conducted, transcribed, and described using thematic analysis. Data collection stopped once saturation occurred (i.e., no new codes or themes emerged during interviews). Two researchers created codes and developed themes in an iterative process; a third researcher verified the representativeness of final themes. This study was approved by the Health Research Ethics Board of Alberta (ID: HREBA.CC-17-0513). Women who persisted described being prepared for side effects and having self-management strategies, strong rationale for AET use, supportive HCPs, and available resources as relevant factors. Women who discontinued described feeling overwhelmed by side effects, information needs, drawbacks of AET, helpful/unhelpful experiences with HCPs, and contextual factors as relevant to their discontinuation. HCPs described health system-related and patient-related barriers, side effect management, and patient-provider interactions as relevant to supporting AET use. The considerable overlap in themes among the three groups suggests broad recognition of salient factors relevant to AET use and that associated strategies to improve use may be acceptable to patients and providers alike. Factors supporting AET use could include the following: education (which may be necessary but insufficient), developing a strong personal rationale for use, being prepared for side effects, having side effect management strategies, reciprocal communication between patients and HCPs, and accessible resources.
format Online
Article
Text
id pubmed-8293219
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-82932192021-07-22 Both “Vitamin L for Life” and “One Milligram of Satan”: A Multi-Perspective Qualitative Exploration of Adjuvant Endocrine Therapy Use after Breast Cancer Toivonen, Kirsti I. Oberoi, Devesh King-Shier, Kathryn Piedalue, Katherine-Ann L. Rash, Joshua A. Carlson, Linda E. Campbell, Tavis S. Curr Oncol Article Adjuvant endocrine therapy (AET) is recommended after hormone receptor-positive breast cancer to reduce risk of recurrence, but adherence is sub-optimal in many women. Behavioral interventions have been ineffective in improving adherence rates to AET. This qualitative descriptive study investigates factors that support women in AET use and suggestions for interventions to improve AET use and management. Interviews with women who persisted with AET (n = 23), women who discontinued AET (n = 15), and healthcare providers (HCPs; oncologists, oncology residents, and pharmacists; n = 9) were conducted, transcribed, and described using thematic analysis. Data collection stopped once saturation occurred (i.e., no new codes or themes emerged during interviews). Two researchers created codes and developed themes in an iterative process; a third researcher verified the representativeness of final themes. This study was approved by the Health Research Ethics Board of Alberta (ID: HREBA.CC-17-0513). Women who persisted described being prepared for side effects and having self-management strategies, strong rationale for AET use, supportive HCPs, and available resources as relevant factors. Women who discontinued described feeling overwhelmed by side effects, information needs, drawbacks of AET, helpful/unhelpful experiences with HCPs, and contextual factors as relevant to their discontinuation. HCPs described health system-related and patient-related barriers, side effect management, and patient-provider interactions as relevant to supporting AET use. The considerable overlap in themes among the three groups suggests broad recognition of salient factors relevant to AET use and that associated strategies to improve use may be acceptable to patients and providers alike. Factors supporting AET use could include the following: education (which may be necessary but insufficient), developing a strong personal rationale for use, being prepared for side effects, having side effect management strategies, reciprocal communication between patients and HCPs, and accessible resources. MDPI 2021-07-05 /pmc/articles/PMC8293219/ /pubmed/34287250 http://dx.doi.org/10.3390/curroncol28040227 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Toivonen, Kirsti I.
Oberoi, Devesh
King-Shier, Kathryn
Piedalue, Katherine-Ann L.
Rash, Joshua A.
Carlson, Linda E.
Campbell, Tavis S.
Both “Vitamin L for Life” and “One Milligram of Satan”: A Multi-Perspective Qualitative Exploration of Adjuvant Endocrine Therapy Use after Breast Cancer
title Both “Vitamin L for Life” and “One Milligram of Satan”: A Multi-Perspective Qualitative Exploration of Adjuvant Endocrine Therapy Use after Breast Cancer
title_full Both “Vitamin L for Life” and “One Milligram of Satan”: A Multi-Perspective Qualitative Exploration of Adjuvant Endocrine Therapy Use after Breast Cancer
title_fullStr Both “Vitamin L for Life” and “One Milligram of Satan”: A Multi-Perspective Qualitative Exploration of Adjuvant Endocrine Therapy Use after Breast Cancer
title_full_unstemmed Both “Vitamin L for Life” and “One Milligram of Satan”: A Multi-Perspective Qualitative Exploration of Adjuvant Endocrine Therapy Use after Breast Cancer
title_short Both “Vitamin L for Life” and “One Milligram of Satan”: A Multi-Perspective Qualitative Exploration of Adjuvant Endocrine Therapy Use after Breast Cancer
title_sort both “vitamin l for life” and “one milligram of satan”: a multi-perspective qualitative exploration of adjuvant endocrine therapy use after breast cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8293219/
https://www.ncbi.nlm.nih.gov/pubmed/34287250
http://dx.doi.org/10.3390/curroncol28040227
work_keys_str_mv AT toivonenkirstii bothvitaminlforlifeandonemilligramofsatanamultiperspectivequalitativeexplorationofadjuvantendocrinetherapyuseafterbreastcancer
AT oberoidevesh bothvitaminlforlifeandonemilligramofsatanamultiperspectivequalitativeexplorationofadjuvantendocrinetherapyuseafterbreastcancer
AT kingshierkathryn bothvitaminlforlifeandonemilligramofsatanamultiperspectivequalitativeexplorationofadjuvantendocrinetherapyuseafterbreastcancer
AT piedaluekatherineannl bothvitaminlforlifeandonemilligramofsatanamultiperspectivequalitativeexplorationofadjuvantendocrinetherapyuseafterbreastcancer
AT rashjoshuaa bothvitaminlforlifeandonemilligramofsatanamultiperspectivequalitativeexplorationofadjuvantendocrinetherapyuseafterbreastcancer
AT carlsonlindae bothvitaminlforlifeandonemilligramofsatanamultiperspectivequalitativeexplorationofadjuvantendocrinetherapyuseafterbreastcancer
AT campbelltaviss bothvitaminlforlifeandonemilligramofsatanamultiperspectivequalitativeexplorationofadjuvantendocrinetherapyuseafterbreastcancer